Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SOPRANO: Stereotactic Radiotherapy Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARP Inhibitor Therapy

NCT05990192 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT05990192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05990192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SOPRANO: Stereotactic Radiotherapy Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARP Inhibitor Therapy
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 2
Overall status
Recruiting
Start date
June 20, 2024
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer recurrent